INPLASY PROTOCOL

Corresponding author:
Michele Marchioni

mic.marchioni@gmail.com

Author Affiliation:
Unversità "G.d'Annunzio" di Chieti

Support: None.

Review Stage at time of this submission: **Completed but not published.**

Conflicts of interest:
None declared.

Micro-RNA predict response to systemic treatments in meta-static renal cell carcinoma patients: results from a systematic review of the literature

Monti, M[1]; Lunardini, S[2]; Magli, IA[3]; Campi, R[4]; Primiceri, G[5]; Berardinelli, F[6]; Amparore, D[7]; Terracciano, D[8]; Lucarelli, G[9]; Schips, L[10]; Ferro, M[11]; Marchioni, M[12].

Review question / Objective: This review aims to offer an overview of the current evolution in the screening of circulating miRNAs as predictors of therapeutic response in patients with mRCC under-going systemic or local treatment and to evaluate their potential for patient identification and stratification.

Condition being studied: Metastatic renal cell carcinoma.

Eligibility criteria: Only studies that compared patients based on miRNA expression (plasmatic, exosomal and urinary) were deemed eligible. The main outcomes of interest were treatment response and overall survival (OS). For studies presenting scores or prognostic models the accuracy reported as Area under the curve (AUC) or C-index, was also considered.

INTRODUCTION

Review question / Objective: This review aims to offer an overview of the current evolution in the screening of circulating miRNAs as predictors of therapeutic response in patients with mRCC under-going systemic or local treatment and to evaluate their potential for patient identification and stratification.

Condition being studied: Metastatic renal cell carcinoma.

METHODS

Participant or population: Patients with metastatic renal cell carcinoma.

Intervention: Systemic treatment (TKI or immunotherapy).

Comparator: Patients stratified according to the miRNA expression.

Study designs to be included: Any (excluded review of the literature, letters or case reports).

Eligibility criteria: Only studies that compared patients based on miRNA expression (plasmatic, exosomal and urinary) were deemed eligible. The main outcomes of interest were treatment response and overall survival (OS). For studies presenting scores or prognostic models the accuracy reported as Area under the curve (AUC) or C-index, was also considered.

Information sources: PubMED (MEDLINE).

Main outcome(s): Overall survival; Response rate.

Quality assessment / Risk of bias analysis: Quality assessment is not mandatory and will be performed based on scales for observational studies.

Strategy of data synthesis: Narrative review.

Subgroup analysis: No pre-specified subgroup analysis will be performed.

Sensitivity analysis: No pre-specified sensitivity analysis will be performed.

Country(ies) involved: Italy.

Keywords: advanced renal cell carcinoma (mRCC); metastatic; immunotherapy; thyroxine-kinase inhibitor; miRNA; plasmatic; urinary; exosomal; liquid biopsy.

Contributions of each author:
Author 1 - Martina Monti.
Author 2 - Susanna Lunardini.
Author 3 - Igino Andrea Magli.
Author 4 - Riccardo Campi.
Author 5 - Giulia Primiceri.
Author 6 - Francesco Berardinelli.
Author 7 - Daniele Amparore.
Author 8 - Daniela Terracciano.
Author 9 - Giuseppe Lucarelli.
Author 10 - Luigi Schips.
Author 11 - Matteo Ferro.
Author 12 - Michele Marchioni.